WU-NK-101
- Generic Name
- WU-NK-101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05470140
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath